Charming Medical Limited Class A Ordinary Shares (MCTA) Revenue History
Annual and quarterly revenue from 2022 to present
MCTA Revenue Over Time (2022–2024)
MCTA Revenue Growth History
2 of 2 years with positive growth- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- +70.4%
- FY2024 revenue growth
- +3.4%
MCTA Revenue Analysis (2022–2024)
Current Revenue & Growth
As of June 29, 2026, Charming Medical Limited Class A Ordinary Shares (MCTA) generated trailing twelve-month (TTM) revenue of $0.
Historical Growth Trajectory
MCTA's historical revenue data shows various trends over time. Charming Medical Limited Class A Ordinary Shares's highest annual revenue of $6.2 million was recorded in 2024, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including CANG (+232.3% YoY), CLOV (+48.4% YoY), and ACMR (+19.7% YoY). Compare MCTA vs CANG →
MCTA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MCTACurrent | $0 | - | - | 22.3% | |
 CANG | $4.8B | +232.3% | +18.6% | -0.4% | |
 CLOV | $1.9B | +48.4% | +23.4% | -4.4% | |
 ACMR | $901M | +19.7% | +41.9% | 12.1% | |
 BTBT | $114M | - | - | -49.8% | |
 AEYE | $40M | +11.6% | +14.5% | -7.9% |
MCTA Historical Revenue Data (2022–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $6.2M | +3.4% | $4.2M | 67.2% | $1.4M | 22.3% |
| 2023 | $6.0M | +70.4% | $3.9M | 65.1% | $1.0M | 16.8% |
| 2022 | $3.5M | - | $1.5M | 42.3% | $-521,336 | -14.8% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MCTA — Frequently Asked Questions
Quick answers to the most common questions about buying MCTA stock.
Is MCTA's revenue growth accelerating or slowing?
MCTA TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is MCTA's revenue history from 2022 to 2026?
Charming Medical Limited Class A Ordinary Shares (MCTA) revenue history spans 2022 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is MCTA's long-term revenue growth rate (CAGR)?
Charming Medical Limited Class A Ordinary Shares's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for MCTA.
Why does MCTA's quarterly revenue fluctuate?
MCTA quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Charming Medical Limited Class A Ordinary Shares's revenue data from 2022 to 2026 shows full historical quarterly detail on this page.
How is MCTA's revenue distributed by segment?
MCTA reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does MCTA's revenue compare to industry peers?
Charming Medical Limited Class A Ordinary Shares (MCTA) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.